Objectives:

Next Stop: Long Acting ART

1. Review the drug development history of rilpivirine LA and cabotegravir tablets/LA
2. Discuss key questions and themes found in patient selection of oral vs long-acting ART
3. Report the data of LA-ART as PrEP

Speaker:
Hans P. Schlecht, MD, MMSc
Department of Medicine
Baystate Infectious Diseases Division

Webinar - Closed

1.00 – AMA PRA Category 1 Credit

1.00 – ANCC Contact Hours

1.00 – BCIPE Instructional Hours